Abstract Library

#4649 Claudin 18.2 overexpression in gastric neuroendocrine tumours

Introduction: Claudin 18.2, is a tissue biomarker physiologically expressed in both healthy gastric mucosa and gastric adenocarcinoma which represents a novel therapeutic target advanced gastric cancer. Various other cancers showed some overexpression of claudin 18.2 opening potential opportunities to agnostic targeted therapy. However, data about claudin 18.2 expression in NENs are poor with only an Eastern study showing higher rate of claudin 18.2 positivity in GEP-NENs, mainly from gastric primary site (27.8%).

Conference:

Presenting Author: Gervaso L

Authors: Gervaso L, Lobrano R, Pisa E, Benini L, Spada F,

Keywords: claudin, gastric NET, biomarker, Neuroendocrine tumour,

#4325 Resection strategies for pulmonary typical carcinoids: Do surgical extents impact survival?

Introduction: While surgical resection of pulmonary typical carcinoid (TC) is primary curative treatment, optimal extent of resection remains debated, with limited data on survival outcomes and prognostic factors guiding management.

Conference:

Presenting Author: Bertolaccini L

Authors: Bertolaccini L, Caffarena G, Spada F, Pisa E, Benini L,

Keywords: neuroendocrine, lung cancer, surgery,

#4200 Risk of venous thromboembolism according to molecular profiling in patients with neuroendocrine carcinoma

Introduction: Venous thromboembolism (VTE) is a common complication in cancer patients, which negatively affects prognosis. Neuroendocrine carcinomas (NEC) are a rare and aggressive diseases, with low responses to treatment and poor prognosis. In this context, the use of molecular profiling is crucial for the identification of druggable alterations. However, data about VTE in NENs are scares, even though retrospective data describes rates in line with other high-risk malignancies.

Conference:

Presenting Author:

Authors: Gervaso L, Winchler C, Pisa E, Benini L, Cella C,

Keywords: VTE, NEC, molecular profiling, neuroendocrine carcinoma, venous thromboembolism,

#3892 Precision medicine in pancreatic MiNEN and other rare pancreatic histologies – A case series from Verona University Hospital

Introduction: Rare tumors of the pancreas represent orphan neoplasms. Better knowledge of their biology will allow more effective treatments to be offered to affected patients.

Conference:

Presenting Author: Trevisani E

Authors: Trevisani E, Mafficini A, Benini L, Borghesani M, Rossi A,

Keywords: Precision medicine, rare pancreas, NGS, gene mutation, MiNEN,

#3891 Exceptional response to Everolimus in a pancreatic NET G3 (pNET) – How NGS can help in treatment choice

Introduction: Exceptional Responders are defined as patients who achieve complete (CR) or partial response (PR) for at least 6 months to a treatment with population PR or CR rate less than 10%, or patients with CR or PR lasting more than three times the median duration of response.

Conference:

Presenting Author: Torresan I

Authors: Torresan I, Mafficini A, Benini L, Borghesani M, Moscarda V,

Keywords: pNET, NGS, G3, everolimus, TSC2,